Vivo Capital
Vivo is a global investment firm focused on healthcare with approximately $5.8 billion in AUM
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Vivo Capital Information
Geographic Data
Address: 575 High St Ste 201
City: Palo Alto
State: CA
Zip: 94301
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Linkedin
Crunchbase
Metrics
2,761,045Website Global Rank
6,244Website Monthly Traffic
Twitter Followers
Description
The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists, entrepreneurs, operating executives, and industry experts. The firm operates as a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.
Contact Phone:
+16506880818
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 7/2019 | IGM Biosciences | Series C | 102M |
| 10/2017 | Harmony Biosciences | Venture Round | 0 |
| 3/2016 | Outpost Medicine | Series A | 41M |
| 7/2017 | VYNE Therapeutics | Series C | 50.5M |
| 10/2003 | Cotherix | Series C | 55M |
| 6/2003 | Prestwick Pharmaceuticals | Series A | 15M |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
| 2/2007 | NextWave Pharmaceuticals | Series B | 40M |
| 8/2007 | Prestwick Pharmaceuticals | Venture Round | 20M |
| 4/2021 | Ronovo Surgical | Series A | - |
| 10/2020 | Gracell Biotechnologies | Series C | 0 |
| 3/2022 | Ocelot Bio | Series A | 0 |
| 2/2017 | Bristol Myers Squibb | Post-IPO Equity | 80M |
| 10/2019 | Arcutis Biotherapeutics | Series C | 94.5M |
| 8/2020 | PatientPop | Series C | 50M |
| 11/2015 | VYNE Therapeutics | Series B | 45M |
| 5/2021 | Rgenta Therapeutics | Seed Round | 18M |
| 10/2019 | dMed | Series B | 50M |
| 3/2020 | Remegen | Private Equity Round | 0 |
| 1/2021 | IO Biotech | Series B | 0 |
| 10/2022 | Neocis | Series D | 0 |
| 10/2020 | Neocis | Series D | 72M |
| 3/2019 | MacuLogix | Series D | 0 |
| 6/2018 | Metacrine | Series C | 65M |
| 7/2020 | Preventice Solutions | Series B | 0 |
| 3/2021 | Ossium Health | Series B | 63M |
| 7/2008 | TRIA Beauty | Series E | 30M |
| 3/2019 | Cerebral Therapeutics | Series A | 7.8M |
| 9/2016 | ReadCoor | Series A | 23M |
| 6/2011 | Revance Therapeutics | Series D | 45M |
| 2/2011 | TRIA Beauty | Venture Round | 26.3M |
| 10/2012 | TRIA Beauty | Venture Round | 7.5M |
| 7/2013 | TRIA Beauty | Private Equity Round | 0 |
| 1/2011 | NextWave Pharmaceuticals | Series C | 45M |
| 11/2018 | Visen Pharmaceuticals | Series A | 0 |
| 10/2002 | Oculex Pharmaceuticals | Series B | 50M |
| 9/2018 | Immune-Onc Therapeutics | Series B | 33M |
| 10/2006 | Prestwick Pharmaceuticals | Series C | 60M |
| 9/2015 | Akari Therapeutics | Post-IPO Equity | 0 |
| 7/2020 | Citrine Medicine | Series A | 0 |
| 11/2022 | Rgenta Therapeutics | Series A | 0 |
| 10/2004 | MacroGenics | Series B | 30.5M |
| 5/2021 | Esco Lifesciences | Series A | 0 |
| 10/2012 | Aclaris Therapeutics | Series A | 21M |
| 8/2017 | Apellis Pharmaceuticals | Series E | 0 |
| 11/2017 | Medeor Therapeutics | Series B | 0 |
| 9/2008 | APT Pharmaceuticals | Series B | 32M |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 6/2022 | DBV Technologies | Post-IPO Equity | 0 |
| 11/2022 | Zenas BioPharma | Series B | 0 |
| 11/2013 | Ocera Therapeutics | Post-IPO Equity | 0 |
| 11/2022 | BioAtla | Post-IPO Equity | 0 |
| 9/2016 | SentreHEART | Series D | 35M |
| 6/2021 | RayzeBio | Series C | 108M |
| 9/2016 | Fortis Therapeutics | Series A | 18M |
| 3/2021 | Fortis Therapeutics | Series A | 0 |
| 4/2020 | Legend Biotech | Series A | 0 |
| 6/2017 | Zai Lab | Series C | 30M |
| 3/2021 | Ventyx Biosciences | Series A | 0 |
| 1/2021 | Design Therapeutics | Series B | 125M |
| 1/2020 | Aligos Therapeutics | Series B | 125M |
| 5/2004 | CAPNIA | Series B | 12M |
| 5/2017 | Aadi | Series A | 23M |
| 12/2022 | Pulmocide | Series C | 0 |
| 11/2022 | Bonum | Series A | 93M |
| 10/2022 | Immunic Therapeutics | Post-IPO Equity | 60M |
| 2/2019 | Bolt | Series B | 54M |
| 9/2021 | INBRACE | Series D | 0 |
| 11/2004 | ViOptix | Series C | 0 |
| 5/2015 | REGENXBIO | Series D | 0 |
| 12/2007 | Revance Therapeutics | Series C | 0 |
| 3/2017 | Angiotech Pharmaceuticals | Venture Round | - |
| 3/2021 | Immune-Onc Therapeutics | Series B | 0 |
| 10/2020 | Olema Oncology | Series C | 85M |
| 10/2022 | VectivBio | Post-IPO Equity | 0 |
| 4/2016 | Kala Pharmaceuticals | Series C | 68M |
| 11/2021 | Ablaze Pharmaceuticals | Series A | 0 |
| 9/2017 | Kadmon | Post-IPO Equity | 80.4M |
| 10/2019 | INBRACE | Series C | 45M |
| 7/2020 | Tranquis Therapeutics | Series A | 30M |
| 3/2021 | OMNI | Series D | - |
| 1/2021 | Kira Pharmaceuticals | Series B | 53.5M |
| 3/2021 | Satsuma Pharmaceuticals | Post-IPO Equity | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 40M |
| 10/2021 | HistoWiz | Series A | 32.3M |
| 11/2012 | MEI Pharma | Post-IPO Equity | 27.5M |
| 12/2020 | dMed | Series C | 100M |
| 8/2022 | Klavi | Series A | 15M |
| 8/2018 | TOT BIOPHARM | Series B | 102M |
| 10/2007 | APT Pharmaceuticals | Series A | 22M |
| 7/2018 | Sinovac Biotech | Post-IPO Equity | 86.7M |
| 3/2004 | Aspreva Pharmaceuticals Corp | Series A | 57M |
| 6/2010 | Vicept Therapeutics | Series A | 16M |
| 5/2014 | Coherus Biosciences | Series C | 54.7M |
| 12/2020 | Provivi | Series C | 0 |
| 11/2007 | Carbylan Therapeutics | Series B | 20M |
| 4/2011 | Eiger BioPharmaceuticals | Series A | 14.5M |
| 7/2019 | Revolution Medicines | Series C | 100M |
| 1/2019 | Innocare | Private Equity Round | 0 |
| 2/2021 | Innocare | Post-IPO Equity | - |
| 12/2014 | Ascendis Pharma | Series D | 60M |
| 11/2016 | Biohaven Pharmaceutical | Venture Round | 80M |
| 3/2023 | EpiBiologics | Series A | 0 |
| 9/2014 | AirXpanders | Series E | 1M |
| 4/2012 | AirXpanders | Series D | 11M |
| 1/2012 | AirXpanders | Series D | 10.3M |
| 9/2018 | AirXpanders | Post-IPO Equity | 15M |
| 8/2013 | Semnur Pharmaceuticals | Venture Round | 6M |
| 1/2021 | Serán Bioscience | Venture Round | - |
| 1/2020 | Tarsus Pharmaceuticals | Series B | 60M |
| 1/2013 | Carbylan Therapeutics | Venture Round | 6M |
| 8/2011 | Ceptaris Therapeutics | Series D | 14.4M |
| 9/2022 | Allakos | Post-IPO Equity | 0 |
| 12/2009 | Revance Therapeutics | Series D | 0 |
| 4/2004 | Revance Therapeutics | Series B | 13M |
| 6/2012 | Ceptaris Therapeutics | Series D | 10M |
| 1/2021 | Visen Pharmaceuticals | Series B | 0 |
| 4/2018 | Poseida Therapeutics | Series B | 0 |
| 1/2000 | Med-eCommerce.com | Venture Round | 2M |
| 8/2020 | ESSA Pharma | Post-IPO Equity | 0 |
| 11/2002 | Copernicus Therapeutics | Venture Round | 2M |
| 10/2014 | Aclaris Therapeutics | Series B | 21M |
| 8/2021 | Neurogastrx | Series B | 60M |
| 9/2015 | Aclaris Therapeutics | Series C | 40M |
| 7/2015 | Gengmei | Series B | - |
| 2/2021 | ASLAN Pharmaceuticals | Post-IPO Equity | 18M |
| 5/2021 | Scientia Vascular | Private Equity Round | 50M |
| 2/2003 | AgraQuest | Venture Round | 9.4M |
| 1/2005 | NextWave Pharmaceuticals | Series A | 10M |
| 11/2017 | Outpost Medicine, LLC | Series A | 20M |
| 11/2011 | Medley Health | Series A | 20M |
| 8/2017 | Amyris | Post-IPO Equity | 50M |
| 2/2018 | Innocare | Private Equity Round | 55M |
| 6/2018 | Cerebral Therapeutics | Series A | 3M |
| 1/2015 | Synapse Biomedical | Venture Round | - |
| 9/2008 | Sagent Pharmaceuticals | Series A | 30M |
| 9/2007 | Sagent Pharmaceuticals | Series A | 53M |
| 12/2021 | Avistone Pharmaceuticals | Private Equity Round | 0 |
| 11/2017 | OMNI | Series C | - |
| 7/2022 | Tebra | Series B | 0 |
| 5/2018 | MEI Pharma | Post-IPO Equity | 75M |
| 8/2017 | Homology Medicines | Series B | 83.5M |
| 11/2015 | Crinetics Pharmaceuticals | Series A | 40M |
| 8/2008 | InteKrin | Series C | 0 |
| 12/2022 | Ronovo Surgical | Series B | - |
| 7/2022 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series D | 0 |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 5/2021 | Larimar Therapeutics | Post-IPO Equity | 0 |
| 6/2017 | Platelet BioGenesis | Series A | 0 |
| 11/2019 | Genetron Health | Series D | 71M |
| 7/2020 | Bolt Biotherapeutics | Series C | 93.5M |
| 1/2007 | InteKrin | Series B | 0 |
| 3/2018 | Crinetics Pharmaceuticals | Series B | 63.5M |
| 6/2020 | Mereo Biopharma | Post-IPO Equity | 0 |
| 11/2011 | Rempex Pharmaceuticals | Series B | 67.5M |
| 7/2016 | Tricida | Series C | 0 |
| 4/2022 | Visirna Therapeutics | Seed Round | 0 |
| 3/2023 | Unicycive Therapeutics | Post-IPO Equity | 0 |
| 4/2014 | Sierra Oncology | Series D | 0 |
| 3/2020 | Rongchang Pharmaceutical | Series A | - |
| 1/2021 | Terns Pharmaceuticals | Series C | 87M |
| 4/2021 | Sera Prognostics | Series E | 0 |
| 6/2013 | AirXpanders | Series E | 9M |
| 6/2012 | SentreHEART | Series C | 26M |
| 11/2020 | Elevation Oncology | Series B | 65M |
| 11/2015 | Celladon | Post-IPO Equity | 39.5M |
| 9/2022 | Ventyx Biosciences | Post-IPO Equity | 0 |
| 2/2020 | ALX Oncology | Series C | 105M |
| 12/2016 | Impel NeuroPharma | Series C | 36M |
| 11/2007 | Ceptaris Therapeutics | Series C | 14.5M |
| 10/2018 | Terns Pharmaceuticals | Series B | 80M |
| 3/2007 | Transcept Pharmaceuticals | Series D | 40M |
| 1/2020 | Cerebral Therapeutics | Series B | 35M |
| 9/2019 | Passage Bio | Series B | 110M |
| 1/2018 | Aligos Therapeutics | Series A | 100M |
| 4/2015 | Nabriva Therapeutics | Series B | 0 |
| 4/2014 | Nora Therapeutics | Series B | 18M |
| 6/2016 | Verona Pharma | Post-IPO Equity | 65.6M |
| 12/2018 | Impel NeuroPharma | Series D | 67.5M |
| 9/2021 | Attralus | Series B | 116M |
| 11/2017 | Tricida | Series D | 0 |
| 7/2020 | Verona Pharma | Private Placement | 200M |
| 3/2021 | BlossomHill Therapeutics | Series A | 71M |
| 2/2009 | Eiger BioPharmaceuticals | Series A | 8.3M |
| 12/2004 | Prestwick Pharmaceuticals | Series B | 37M |
| 5/2021 | Aerobiotix | Venture Round | 0 |
| 1/2010 | Neomend | Series D | 30M |
| 6/2009 | Sagent | Series A | 30M |
| 4/2019 | Poseida Therapeutics | Series C | 0 |
| 7/2022 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series D | 0 |
| 7/2022 | Tebra | Series B | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 0 |
| 6/2022 | DBV Technologies | Post-IPO Equity | 0 |
| 4/2022 | Visirna Therapeutics | Seed Round | 0 |
| 3/2022 | Ocelot Bio | Series A | 0 |
| 12/2021 | Avistone Pharmaceuticals | Private Equity Round | 0 |
| 11/2021 | Ablaze Pharmaceuticals | Series A | 0 |
| 10/2021 | HistoWiz | Series A | 0 |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
